Affiliations: [a]
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| [b]
Department of Pathology, University of Texas, San Antonio, San Antonio, TX, USA
| [c]
Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| [d]
Mesulam Center for Cognitive Neurology and Alzheimer’s Disease, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Correspondence:
[*]
Correspondence to: Rudolph J. Castellani, MD, 710 N Fairbanks Court, Olson Pavilion 2-514, Chicago, IL 60611, USA. Tel.: +1 312 694 6852; Fax: +1 312 926 9830; E-mail:[email protected].
Abstract: Host responses to anti-amyloid-β (Aβ) antibody therapy are evident in neuroimaging changes and clinical symptoms in a subset of clinical trial subjects receiving such therapy. The pathological basis for the imaging changes and clinical symptoms is not known, nor is the precise mechanism of Aβ clearing. We report the autopsy findings in a 65-year-old woman who received three open label infusions of the experimental anti-Aβ drug lecanemab over about one month. Four days after the last infusion, she was treated with tissue plasminogen activator for acute stroke symptoms and died several days later with multifocal hemorrhage. Neuropathological examination demonstrated histiocytic vasculitis involving blood vessels with cerebral amyloid angiopathy. Fragmentation and phagocytosis of vascular Aβ were present throughout the cerebral cortex. Phagocytosis of parenchymal Aβ plaques was noted. Changes suggestive of Aβ and phosphorylated tau “clearing” were also noted. The findings overall suggest that anti-Aβ treatment stimulated a host response to Aβ, i.e., target engagement. The findings also provide evidence that amyloid-related imaging abnormalities might be indicative of an Aβ phagocytic syndrome within cerebral vasculature and parenchymal brain tissue in some cases.
